BCL2 and acute myeloid leukemia: In the randomized phase III trial VIALE‐A, hypomethylating agents (HMA) in combination with the BCL‐2 inhibitor Venetoclax were superior to HMA alone in elderly AML patients ineligible for intensive chemotherapy [26].